Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on April 25, 2014.
- Share Price: The transaction price was $55.76 per ADS.
- Involved Parties: Dr. M. Slaoui (Director) had no change in allocation; Dr. K. Slaoui (Connected Person) received an increase of 3 ADSs.
- Plan Details: The transaction relates to the GSK 401K plan, which is notionally held in GSK ADSs.